TICKERNERD
Menu
RMDHealthcare · Medical Instruments & Supplies

RMD Stock Forecast: ResMed, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$220
−0.50% on the day

The 19 Wall Street analysts covering ResMed, Inc. hold a median 12-month price target of $235 — +6.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 8 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$32.9B
Ticker Nerd rank
70 / 100
Median analyst target
$235
Analysts covering
19
Revenue$1.5B+8.6% y/y
Operating income$448.7M
Net income$383.4M
Free cash flow$397.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.9%
1M
+4.1%
YTD
−7.9%
1Y
−20.4%
From 52W high
−21.5%
From 52W low
+20.7%
$182
$280
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ResMed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
96
Quality
96
Value
88
Issuance
84
Growth
61
Revisions
53
Accruals
43
Momentum
29
Size
7

Volatility (96): The share price has been relatively steady.

Momentum (29): The shares have been drifting down relative to others.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Oct 25Jan 26Apr 26Jul 26RMDHigh $320Median $235Low $175

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
7 Buy11 Hold1 Sell
Low $175Median $235High $320

The green dot is the last close — the median target sits +6.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
31 Aug 2026KeybancMaintainsOverweight$255 → $267
19 Aug 2026Rothschild & CoInitiatesNeutral$230
19 Aug 2026Rothschild & CoInitiatesNeutral—
7 Aug 2026KeybancMaintainsOverweight$260 → $255
7 Aug 2026KeybancMaintainsOverweight—
7 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026Piper SandlerMaintainsNeutral$233 → $225
7 Aug 2026RBC CapitalMaintainsSector Perform—
7 Aug 2026RBC CapitalMaintainsSector Perform$234 → $244
7 Aug 2026Wells FargoMaintainsEqual-Weight—
7 Aug 2026Wells FargoMaintainsEqual-Weight$225 → $215
15 July 2026MizuhoMaintainsOutperform—
15 July 2026MizuhoMaintainsOutperform$235 → $220
13 July 2026CitigroupDowngradeNeutral$270 → $235
13 July 2026CitigroupDowngradeNeutral—
10 July 2026JefferiesMaintainsHold—
10 July 2026JefferiesMaintainsHold$240 → $225
8 July 2026RBC CapitalMaintainsOutperform$321 → $276
8 July 2026RBC CapitalMaintainsOutperform—
8 July 2026Wells FargoMaintainsEqual-Weight$227 → $225

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, ResMed, Inc. returned −20.4% against +18.5% for the S&P 500, dividends included.

RMD vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26RMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.5%
Analysts raising
2
Analysts cutting
3
Fundamentals

ResMed, Inc. (RMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.1×

Cheaper than 36% of US stocks

Price / sales
5.6×

Cheaper than 23% of US stocks

Price / book
4.8×

Cheaper than 22% of US stocks

EV / EBITDA
15.4×

Cheaper than 22% of US stocks

Growth & margins
Revenue growth (YoY)
8.6%

Higher than 48% of US stocks

Earnings growth (YoY)
1.0%

Higher than 37% of US stocks

Gross margin
58.8%

Higher than 72% of US stocks

Operating margin
30.9%

Higher than 88% of US stocks

Net margin
26.9%

Higher than 87% of US stocks

Returns & dividend
Return on equity
24.3%

Higher than 85% of US stocks

Return on assets
14.0%

Higher than 96% of US stocks

Dividend yield
1.2%

Higher than 28% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ResMed, Inc. (RMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ResMed, Inc. has a market value of $32.9B and an enterprise value of $32.3B.

  • Revenue in the twelve months to 30 June 2026: $5.7B. The latest quarter grew 8.6% year on year.

  • Net income over the same four quarters: $1.5B, a 26.9% net margin.

  • Diluted earnings per share, trailing twelve months: $10.43.

  • Free cash flow in the twelve months to 30 June 2026: $1.6B.

  • ResMed, Inc. spent $700.0M on share buybacks and $349.7M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 144.2M.

  • Trailing P/E: 21.1×; forward P/E: 16.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.19%, paying out 23% of earnings.

  • ResMed, Inc. employs 11,370 people — $497K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

RMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
RMDResMed, Inc.$32.9B
70
ALCAlcon AG$34.4B
69
WSTWest Pharmaceutical Services, Inc.$24.3B
93
MDLNMedline, Inc.$45.6B
19
BDXBecton, Dickinson & Co.$49.3B
93
SOLVSolventum Corp.$15.6B
89
COOThe Cooper Cos., Inc.$13.3B
81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ResMed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RMD news & analysis

Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference

GlobeNewsWire · 27 Aug 2026neutral

Resmed announced that CEO Mick Farrell and CFO Aaron Bloomer will attend and present a webcast at the 24th Annual Morgan Stanley Global Healthcare Conference in New York on September 15, 2026. The presentation is scheduled to begin at approximately 10:00 a.m. Eastern Time.

Why it matters — A Resmed watcher would care because the company's senior leadership will be presenting to investors at a major healthcare conference, offering an opportunity to hear directly from management.

Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor

GlobeNewsWire · 17 Aug 2026neutral

Resmed announced that Carol Burt will become Lead Director on November 15, 2026, succeeding Ron Taylor, who is not standing for reelection at the 2026 Annual Meeting on November 18, 2026, and will retire after more than 21 years of service.

Why it matters — Board leadership changes, including the successor to a long-serving director, can signal the direction of governance and oversight for Resmed shareholders.

Dividend Champion, Contender, And Challenger Highlights: Week August 16

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published a weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers, listing companies that changed their dividends and those with upcoming ex-dividend dates. The article notes the week of August 16.

Why it matters — ResMed watchers may track such summaries to stay informed of dividend-related activity relevant to the company's status as a dividend-paying stock.

ResMed Q4 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

ResMed reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, driven by increased demand for sleep devices and masks. Non-GAAP earnings per share rose 16% to $2.95, and gross margin expanded despite continued inflation in electronic components and freight.

Why it matters — The quarter showed stronger demand for sleep devices and masks alongside improved profitability, key indicators for investors tracking ResMed's growth trajectory.

RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y

Zacks Investment Research · 7 Aug 2026negative

ResMed reported fourth-quarter earnings and revenues that beat analyst estimates, with revenues rising year over year. However, shares fell after the company issued fiscal 2027 revenue guidance that trailed the consensus mark.

Why it matters — RMD watchers would care because the stock's decline despite an earnings beat signals that forward-looking guidance, rather than past-quarter results, is now driving market sentiment.

FAQ

Frequently asked questions about RMD stock

What is the RMD stock price forecast for 2026-2027?

The 19 Wall Street analysts covering ResMed, Inc. have a median 12-month price target of $235, with estimates ranging from $175 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RMD stock a buy right now?

Of the 19 analysts covering ResMed, Inc., 7 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ResMed, Inc. 70 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RMD?

As at 8 Sept 2026, ResMed, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

Will RMD stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +6.8% from the last close, and Ticker Nerd's factor model ranks ResMed, Inc. 70 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RMD stock forecast for 2030?

No analyst covering ResMed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $320 over the next 12 months.

How has RMD stock performed over the past year?

ResMed, Inc. returned -20.4% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ResMed, Inc. do?

ResMed Inc. is a global medical technology and digital health company focused on sleep health, respiratory care, and out-of-hospital care.

What is the latest news on RMD?

The most recent item we track (GlobeNewsWire, 27 Aug 2026): "Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference". Resmed announced that CEO Mick Farrell and CFO Aaron Bloomer will attend and present a webcast at the 24th Annual Morgan Stanley Global Healthcare Conference in New York on September 15, 2026. The presentation is scheduled to begin at approximately 10:00 a.m. Eastern Time.

Company

About ResMed, Inc.

ResMed Inc. is a global medical technology and digital health company focused on sleep health, respiratory care, and out-of-hospital care. ResMed develops and markets cloud-connected medical devices, including positive airway pressure systems, masks, home ventilators, and related accessories used to diagnose and manage sleep apnea and other chronic respiratory disorders. The company also provides software and connected-care platforms that support home healthcare, post-acute care, and care coordination for providers, patients, and caregivers. Its product portfolio serves hospitals, sleep clinics, home medical equipment suppliers, and long-term care organizations across global markets. ResMed Inc. plays an important role in the healthcare market by combining medical devices with software to improve treatment delivery, patient monitoring, and care management in home and clinical settings.

CEO Mr. Michael J. Farrell BE, MBA, SM · 11,370 employees · United States · https://www.resmed.com